Glacier Aminos has Retatrutide in stock!
Stack codes HEATUP10 and PROF10 for 2 discounts. 🔥
Glacier Aminos also carries other popular metabolic and weight loss peptides, including Tirzepatide, Semaglutide, and Cagrilintide.
99% HPLC purity, with identity, endotoxin, and heavy-metal testing; batch-traceable public COAs from US labs.
https://t.co/TvW5KTSwD4
#GLP1#GLP1
Peptide Codes
TX Drugs, Prescriptions & Therapeutics
0 engagementsGlacier Aminos has Retatrutide in stock!
Stack codes HEATUP10 and PROF10 for 2 discounts. 🔥
Glacier Aminos also carries other popular metabolic and weight loss peptides, including Tirzepatide, Semaglutide, and Cagrilintide.
99% HPLC purity, with identity, endotoxin, and heavy-metal testing; batch-traceable public COAs from US labs.
https://t.co/Up0iOwsG5Y
#GLP1#GLP1
Peptide Codes
TX Drugs, Prescriptions & Therapeutics
0 engagementsHappy Wednesday! End with some work at Hotworx Atascocita (Atascocita, TX - Lake Houston) BANTU Vitality 1st Phorm CMD Wellness Great tasting quality Protein here https://t.co/Z27xyXjWIl #cmdwellness #semaglutide #hrt #1stphorm https://t.co/t0AxcmCVHi
#GLP1
CMD Wellness✓
TX Drugs, Prescriptions & Therapeutics
0 engagementsHappy Tuesday! End with some work at Hotworx Atascocita (Atascocita, TX - Lake Houston) 1st Phorm CMD Wellness BANTU Vitality Siya Health Great tasting quality Protein here https://t.co/Z27xyXjWIl #cmdwellness #semaglutide #hrt #1stphorm https://t.co/MxoYWPOWLH
#GLP1
CMD Wellness✓
TX Drugs, Prescriptions & Therapeutics
0 engagementsEli Lilly's Oral GLP-1 Orforglipron Outperforms Oral Semaglutide in Phase-III Diabetes Trials; 57% Greater A1C Reduction and 73% Better Weight Loss at Highest Dose — USFDA Submission Planned by End of Q2
The Trial Results — ACHIEVE Programme
Three Phase-III trials: ACHIEVE-3, ACHIEVE-2, and ACHIEVE-5
ACHIEVE-3: orforglipron vs oral semaglutide; ACHIEVE-2 & 5: vs dapagliflozin and placebo added to insulin glargine
Orforglipron recorded average A1C reductions of 1.9% (9mg dose) and 2.2% (17.2mg dose) after 52 weeks
Oral semaglutide recorded only 1.1% and 1.4% A1C reductions respectively
Translated to 57.1% greater relative reduction in A1C at highest-dose comparison
73.6% greater relative reduction in body weight vs oral semaglutide at highest dose
Key Differentiator — Convenience Factor
Orforglipron is a once-daily pill — no food or water restrictions
Oral semaglutide requires specific dosing conditions
Tested at approved diabetes doses — real-world comparable assessment
Dr Julio Rosenstock, University of Texas Southwestern: first head-to-head data on oral GLP-1s in Type-II diabetes
Cardiovascular Benefits — Beyond Sugar Control
Demonstrated clinically meaningful improvements across all three trials in cardiovascular risk markers:
Non-HDL cholesterol
HDL cholesterol
VLDL cholesterol
Total cholesterol
Systolic blood pressure
Triglycerides
India Market Context — Semaglutide Slowdown
Semaglutide consumption in India had established a base post aggressive generic pricing
Growth momentum slowing as significant proportion of eligible patients already onboarded
Pharmarack data: semaglutide recorded 6% MoM value growth in May 2026 vs 50% in April
Unit growth slowed to 12% in May from 88% the previous month
Market moving from launch-driven expansion to patient retention and long-term therapy adherence
Regulatory & Commercial Roadmap
Lilly plans to submit orforglipron to USFDA by end of Q2 under Commissioner's National Priority Review Voucher programme
Positioned as potential attractive first-line therapy option in primary care for Type-II diabetes
Thomas Seck, Lilly Cardiometabolic Health: drug has potential for millions of Type-II diabetes patients
Core Theme
Eli Lilly's orforglipron is shaping up to be a formidable challenger in the oral GLP-1 space — outperforming semaglutide on both A1C reduction and weight loss while offering the critical convenience of no food or water restrictions. With a broad cardiovascular benefit profile, an imminent USFDA filing, and a slowing semaglutide market creating an opening, Lilly is well-positioned to capture significant share in what is becoming the most competitive segment in global diabetes care.
#GLP1#diabetes
The Cloaked Gaze 👀✓
TX Drugs, Prescriptions & Therapeutics
10 engagementsHappy Sunday! Start with some work at Hotworx Atascocita (Atascocita, TX - Lake Houston) 1st Phorm Siya Health BANTU Vitality CMD Wellness Great tasting quality Protein here https://t.co/Z27xyXjWIl #cmdwellness #semaglutide #hrt #1stphorm https://t.co/pZjWYVK0zj
#GLP1
CMD Wellness✓
TX Drugs, Prescriptions & Therapeutics
0 engagements